I
ITi Health
Developer of proprietary technology that identifies a protein biomarker in the early stages of pancreatic cancer
About ITi Health
Based in Charlottesville, Virginia, iTi Health, Inc. operates within the biotechnology sector, focusing on the development of novel diagnostics and therapies for several challenging cancers, including pancreatic, ovarian, esophageal, and head and neck cancers. Founded in November 2010, the company's core mission is to create personalized therapies for diseases with significant unmet medical needs.
The company's strategy is centered around two main product lines: plectin-targeted imaging and plectin-targeted therapeutics. iTi Health holds exclusive, global rights to the targeting agent compositions and the use of plectin for both diagnostic and therapeutic applications in human diseases. This positions the company to develop proprietary technology that can identify a protein biomarker in the early stages of pancreatic cancer. The business model appears to be rooted in the research and development of these biotechnologies, with the eventual goal of commercializing these products, likely through partnerships, licensing, or direct sales to healthcare providers and pharmaceutical companies.
The leadership team includes Kim Kelly, who serves as the CEO and CSO. Dr. Kelly is also an Assistant Professor of Biomedical Engineering at the University of Virginia, bringing a strong academic and research-oriented background to the company's operations. Colin Rolph is also listed as part of the team. The company is structured as a C-corp and, as of earlier records, its products are in the development stage.
Source: Dealroom company dataNews
Open roles
ITi Health in the Charlottesville ecosystem
The ITi Health office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
CIT GAP Funds
Series B and later1 investor entered at this stage
Halyard Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about ITi Health on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ITi Health on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


